详情页 - 聚合机构库演示平台

当前位置：首页 > 详情页

Tumor mutation score is more powerful than tumor mutation burden in predicting response to immunotherapy in non-small cell lung cancer

81| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

单位： [1]Wuhan Univ, Dept Oncol, Renmin Hosp, Wuhan, Peoples R China [2]Huazhong Univ Sci & Technol, Tongji Hosp, Dept Oncol, Wuhan, Peoples R China [3]Chinese Acad Med Sci & Peking Union Med Coll, Dept Thorac Surg, Natl Canc Ctr, Natl Clin Res Ctr Canc,Canc Hosp, .18 Panjiayuannanli, Beijing 100021, Peoples R China

出处：

DOI：

ISSN：

关键词： Tumor mutation score Tumor mutation burden Immunotherapy Biomarker Lung cancer

摘要：

Tumor mutation burden (TMB) predicts response to immunotherapy in non-small cell lung cancer (NSCLC). The current TMB evaluation is expensive and not satisfactory. Here, novel tumor mutation score (TMS) was defined as the number of genes with mutations in candidate genes and compared with TMB and PD-L1 in 240 NSCLC patients and validated in 34 NSCLC patients. Eighteen genes were significantly associated with longer progression-free survival (PFS) or better response. The number of mutated genes within 18 favorable genes were defined as TMS18. TMS18 (HR = 0.307, P < 0.001) had smaller hazard ratio and P value than TMB (HR = 0.455, P = 0.004) and PD-L1 expression (HR = 0.403, P = 0.005) in survival analysis. Moreover, TMS18 had significantly higher AUC than TMB and TMS18 combined with PD-L1 improved the accuracy. Universal cutoff of TMS18 enriched more patients with benefits. These findings were largely consistent in the validation cohort. Taken together, TMS18 was more powerful than TMB in predicting response of ICIs in NSCLC. Selective TMS was more feasible and cost-effective than unselective TMB. TMS18 combined with PD-L1 might yield better efficiency in predicting response of ICIs in NSCLC with future validation in larger cohorts.

基金：

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2020]版：

大类 | 2 区医学

小类 | 2 区免疫学 3 区肿瘤学

最新[2025]版：

大类 | 3 区医学

小类 | 3 区免疫学 3 区肿瘤学

JCR分区：

出版当年[2019]版：

Q1 IMMUNOLOGY Q1 ONCOLOGY

最新[2023]版：

Q1 ONCOLOGY Q2 IMMUNOLOGY

影响因子： 4.6 最新[2023版] 5.4 最新五年平均 5.442 出版当年[2019版] 4.781 出版当年五年平均 4.9 出版前一年[2018版] 6.968 出版后一年[2020版]

第一作者：

第一作者单位： [1]Wuhan Univ, Dept Oncol, Renmin Hosp, Wuhan, Peoples R China

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Tumor Mutation Score Is More Powerful Than Tumor Mutation Burden in Predicting Response to Immunotherapy in Non-Small Cell Lung Cancer [2]Tumor Mutation Score Is More Powerful Than Tumor Mutation Burden in Predicting Response to Immunotherapy in Non-Small Cell Lung Cancer [3]Novel tumor mutation score versus tumor mutation burden in predicting survival after immunotherapy in pan-cancer patients from the MSK-IMPACT cohort [4]Development of Tumor Mutation Burden-Related Prognostic Model and Novel Biomarker Identification in Stomach Adenocarcinoma [5]CD1B is a Potential Prognostic Biomarker Associated with Tumor Mutation Burden and Promotes Antitumor Immunity in Lung Adenocarcinoma [6]Identification of BAP1 mutation as a common mutation correlated with tumor mutation burden and immune infiltration in kidney renal clear cell carcinoma [7]The Prognosis-Predictive and Immunoregulatory Role of SUMOylation Related Genes: Potential Novel Targets in Prostate Cancer Treatment [8]A Four-Cell-Senescence-Regulator-Gene Prognostic Index Verified by Genome-Wide CRISPR Can Depict the Tumor Microenvironment and Guide Clinical Treatment of Bladder Cancer [9]Ferroptosis Patterns and Tumor Microenvironment Infiltration Characterization in Bladder Cancer [10]Analysis of m6A Methylation Modification Patterns and Tumor Immune Microenvironment in Breast Cancer